Desmosomes and
fasciae adhaerentes (sing.,
fascia adhaerens), the latter also termed adherens junctions are responsible for cell–cell adhesion and are often subsumed under the collective term adhering junctions. In various epithelia, like in the multistratified skin epithelium, desmosomes, and adherens junctions are distinct structures with only few shared components, such as, e.g., plakoglobin (Cowin et al.,
1986). Desmosomes anchor the cytoskeletal intermediate filaments and
fasciae adhaerentes the cytoskeletal actin microfilaments (Franke,
2009; Dubash and Green,
2011). In the heart things are quite different and more complex. Adult mammalian cardiomyocytes are for the most part connected by adhering junctions termed
areae compositae (sing.,
area composita) or composite junctions to highlight their hybrid character (Franke et al.,
2006,
2009; Pieperhoff et al.,
2010a). Composite junctions consist of both, typical desmosomal and typical adherens junction proteins (Franke et al.,
2006; Pieperhoff et al.,
2010a). In composite junctions desmosomal proteins are therefore indirectly involved in supporting the myofibrillar actin anchorage in N-cadherin mediated cell–cell adhesion complexes (Goossens et al.,
2007).
Today it is generally accepted that arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is in most of the cases caused by mutations in desmosomal genes. Disease causing mutations have been found in genes encoding for the desmosomal plaque components plakophilin-2, desmoplakin, and plakoglobin and the transmembrane desmosomal cadherins desmoglein-2 and desmocollin-2 (see, e.g., Rampazzo et al.,
2002; Norman et al.,
2005; Pilichou et al.,
2006; Thiene et al.,
2007; for further references please see Rickelt and Pieperhoff,
2012). Although rare, mutations in some non-desmosomal proteins such as, desmin (see Figure ), transforming growth factor-β3 (TGFB3), transmembrane protein 43 (TMEM43), ryanodine receptor 2 (RYR2), lamins A and C, striatin and titin have also been associated with ARVC/D development (Rampazzo et al.,
1995; Beffagna et al.,
2005; Merner et al.,
2008; Klauke et al.,
2010; Meurs et al.,
2010; Quarta et al.,
2011; Taylor et al.,
2011). ARVC/D is characterized by a progressive replacement of contractile heart muscle tissue by fibrotic and fat tissue (“fibrofatty replacement”) and severe arrhythmogenesis often followed by sudden cardiac mortality. Fibrofatty replacement was often but not exclusively found in the right ventricle (Bauce et al.,
2005; Lindstrom et al.,
2005; Thiene et al.,
2007). Homozygous mutations in plakoglobin cause a syndromic disease form called “Naxos disease” involving skin and hair abnormalities in addition to the ARVC/D-type fibrofatty replacement of the myocardium (Protonotarios et al.,
2001).
Functional alterations in ARVC/D most likely include alterations in gap junctions and sodium channels as a result from adhering junction defects (Kaplan et al.,
2004; Sato et al.,
2009,
2011). Furthermore, suppressed Wnt-signaling by nuclear plakoglobin may be involved in fibrofatty replacement and ARVC/D phenotype development (Garcia-Gras et al.,
2006; MacRae et al.,
2006; Hirschy et al.,
2010; Lombardi et al.,
2011). In earlier investigations, cell contacts have been found to be an independent factor for cardiomyocyte survival
in vitro (Clark et al.,
1998) showing the general importance of these structures beside their important role in cell–cell adhesion.
Overexpression of mutant desmosomal genes or introduction of mutant desmosomal genes in mice (Pilichou et al.,
2009) and other animal model systems (zebrafish) will help further to understand ARVC/D disease development and treatment (Macrae,
2010; Fabritz et al.,
2011).
Recently, screening for novel candidates of ARVC/D causing genes have been for the first time extended to typical
fascia adhaerens components, yet without striking results (Christensen et al.,
2011). However, many other candidate genes, localized in the composite junctions within the intercalated disk may be included in future screenings (e.g., Kargacin et al.,
2006; Otten et al.,
2010; Seeger et al.,
2010). Hopefully, this will improve molecular diagnostics, genetic testing, and genetic management of this disease (Fressart et al.,
2010).